Manju Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manju Sharma has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Mohammad Adil
Department of Pharmacology, School of Pharmaceutical Education &Research, Jamia Hamdard (Hamdard University), New Delhi 110062, India
11 shared publicationsPinaki Ghosh
Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth, Pune, India
7 shared publications- Avinash Kumar Singh
Jamia Hamdard
5 shared publications Prem Kapur
5 shared publicationsAzharuddin
Department of Pharmaceutical Medicine, Division of Pharmacology, School of Pharmaceutical Education and Research, New Delhi, India
4 shared publicationsDinesh Bhurani
Rajiv Gandhi Cancer Institute and Research Centre
4 shared publications
Latest Publications
- 10 November 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 254
Carbonyl stress as the missing molecular link between diabetes and neurodegeneration: a unified mechanistic framework for type 3 diabetes
- 10 November 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 254
Carbonyl stress as the missing molecular link between diabetes and neurodegeneration: a unified mechanistic framework for type 3 diabetes
- 9 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10)
Integrated In Silico and In Vitro Investigation of Chromene Derivatives as Potential Antidiabetic Agents in 3T3‐L1 Cells
Type 2 diabetes mellitus is characterized by a progressive decline in insulin sensitivity and represents an important therapeutic target for improving glucose homeostasis. Chromen‐derived compounds have attracted interest as potential antidiabetic agents because of their diverse pharmacological activities. Drug‐likeness and pharmacokinetic properties were evaluated using ADME profiling. In silico docking and simulation analyses were performed to characterize ligand–protein interactions and evaluate the stability complex with carbohydrate‐hydrolyzing enzymes. In vitro studies included MTT assay for cell viability/tolerability, α‐glucosidase and α‐amylase inhibition assays and 2‐deoxyglucose (2‐DG) uptake in 3T3‐L1 cells. Conventional RT‐PCR was further performed to assess PI3K and GLUT‐4 mRNA expression. The 2‐DG assay provided a functional measure of cellular glucose uptake under the experimental conditions and was not designed to directly establish insulin sensitization. Both compounds showed favorable predicted drug‐like and pharmacokinetic properties. Docking and MD analyses predicted favorable ligand–enzyme interactions and complex stability. Experimentally, 7‐methoxy‐3‐Phenyl‐4H‐Chromen‐4‐one showed stronger α‐glucosidase inhibition, higher 2‐DG uptake and marked upregulation of PI3K and GLUT‐4 expression, whereas 7,8‐Dihydroxy‐3‐(4‐hydroxyphenyl)‐4H‐chromen downregulated PI3K, modestly increased GLUT‐4 and showed lower 2‐DG uptake. The findings indicate potential antidiabetic activity through complementary effects on carbohydrate digestion and cellular glucose handling. 7‐methoxy‐3‐Phenyl‐4H‐Chromen‐4‐one showed the most consistent response among the chromen derivatives evaluated and emerged as a candidate for further investigation. The present findings do not establish direct activation of insulin‐signaling pathway or reversal of insulin resistance. Comprehensive mechanistic investigations, together with in vivo validation, are needed to further substantiate the therapeutic potential of the compound.
- 9 October 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (10)
Integrated In Silico and In Vitro Investigation of Chromene Derivatives as Potential Antidiabetic Agents in 3T3‐L1 Cells
Type 2 diabetes mellitus is characterized by a progressive decline in insulin sensitivity and represents an important therapeutic target for improving glucose homeostasis. Chromen‐derived compounds have attracted interest as potential antidiabetic agents because of their diverse pharmacological activities. Drug‐likeness and pharmacokinetic properties were evaluated using ADME profiling. In silico docking and simulation analyses were performed to characterize ligand–protein interactions and evaluate the stability complex with carbohydrate‐hydrolyzing enzymes. In vitro studies included MTT assay for cell viability/tolerability, α‐glucosidase and α‐amylase inhibition assays and 2‐deoxyglucose (2‐DG) uptake in 3T3‐L1 cells. Conventional RT‐PCR was further performed to assess PI3K and GLUT‐4 mRNA expression. The 2‐DG assay provided a functional measure of cellular glucose uptake under the experimental conditions and was not designed to directly establish insulin sensitization. Both compounds showed favorable predicted drug‐like and pharmacokinetic properties. Docking and MD analyses predicted favorable ligand–enzyme interactions and complex stability. Experimentally, 7‐methoxy‐3‐Phenyl‐4H‐Chromen‐4‐one showed stronger α‐glucosidase inhibition, higher 2‐DG uptake and marked upregulation of PI3K and GLUT‐4 expression, whereas 7,8‐Dihydroxy‐3‐(4‐hydroxyphenyl)‐4H‐chromen downregulated PI3K, modestly increased GLUT‐4 and showed lower 2‐DG uptake. The findings indicate potential antidiabetic activity through complementary effects on carbohydrate digestion and cellular glucose handling. 7‐methoxy‐3‐Phenyl‐4H‐Chromen‐4‐one showed the most consistent response among the chromen derivatives evaluated and emerged as a candidate for further investigation. The present findings do not establish direct activation of insulin‐signaling pathway or reversal of insulin resistance. Comprehensive mechanistic investigations, together with in vivo validation, are needed to further substantiate the therapeutic potential of the compound.
- 5 October 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (5) , 327
Gastroprotective effects of ethanolic leaf extracts of Matricaria chamomilla L. and Albizia lebbeck L. against indomethacin-induced gastric ulcer in Wistar rats: modulation of oxidative stress and inflammatory cytokines
Indomethacin-induced gastric ulceration involves oxidative stress, inflammation, and impairment of gastric mucosal defense. This study evaluated the gastroprotective effects of ethanolic leaf extracts of Matricaria chamomilla L. (MC) and Albizia lebbeck L. (AL), individually and in combination, in an indomethacin-induced gastric ulcer model in Wistar rats. Animals were randomly divided into 11 experimental groups (n = 6 per group) and treated orally for 10 days with MC or AL (250 or 500 mg/kg), their combinations (total doses of 250 or 500 mg/kg), or ranitidine (50 mg/kg). Gastric injury was assessed by ulcer index, gastric mucus, oxidative stress markers, inflammatory cytokines, PGE2, and histopathology. HPTLC fingerprinting supported the qualitative presence of rutin in MC and quercetin in AL. Indomethacin increased the ulcer index to 2.24 ± 0.24 and reduced gastric mucus to 1.45 ± 0.23 µg/g. The 500 mg/kg MC + AL combination reduced the ulcer index to 1.02 ± 0.13, increased gastric mucus to 2.66 ± 0.13 µg/g, decreased TBARS to 2.58 ± 0.14 nmol/mg protein, and increased GSH to 353.09 ± 24 µg/mg protein. TNF-α, IL-1β, and IL-6 decreased from 54 ± 3.1, 31 ± 1.6, and 23 ± 1.8 to 17 ± 0.9, 15 ± 0.7, and 7 ± 0.8 pg/mL, respectively, while PGE₂ increased from 11 ± 1.0 to 25 ± 1.4 pg/mL (p < 0.01). Histopathology supported preservation of gastric mucosal architecture. Overall, MC and AL extracts exhibited gastroprotective effects associated with attenuation of oxidative and inflammatory responses and preservation of mucosal defense. Graphical Abstract
- 5 October 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (5) , 327
Gastroprotective effects of ethanolic leaf extracts of Matricaria chamomilla L. and Albizia lebbeck L. against indomethacin-induced gastric ulcer in Wistar rats: modulation of oxidative stress and inflammatory cytokines
Indomethacin-induced gastric ulceration involves oxidative stress, inflammation, and impairment of gastric mucosal defense. This study evaluated the gastroprotective effects of ethanolic leaf extracts of Matricaria chamomilla L. (MC) and Albizia lebbeck L. (AL), individually and in combination, in an indomethacin-induced gastric ulcer model in Wistar rats. Animals were randomly divided into 11 experimental groups (n = 6 per group) and treated orally for 10 days with MC or AL (250 or 500 mg/kg), their combinations (total doses of 250 or 500 mg/kg), or ranitidine (50 mg/kg). Gastric injury was assessed by ulcer index, gastric mucus, oxidative stress markers, inflammatory cytokines, PGE2, and histopathology. HPTLC fingerprinting supported the qualitative presence of rutin in MC and quercetin in AL. Indomethacin increased the ulcer index to 2.24 ± 0.24 and reduced gastric mucus to 1.45 ± 0.23 µg/g. The 500 mg/kg MC + AL combination reduced the ulcer index to 1.02 ± 0.13, increased gastric mucus to 2.66 ± 0.13 µg/g, decreased TBARS to 2.58 ± 0.14 nmol/mg protein, and increased GSH to 353.09 ± 24 µg/mg protein. TNF-α, IL-1β, and IL-6 decreased from 54 ± 3.1, 31 ± 1.6, and 23 ± 1.8 to 17 ± 0.9, 15 ± 0.7, and 7 ± 0.8 pg/mL, respectively, while PGE₂ increased from 11 ± 1.0 to 25 ± 1.4 pg/mL (p < 0.01). Histopathology supported preservation of gastric mucosal architecture. Overall, MC and AL extracts exhibited gastroprotective effects associated with attenuation of oxidative and inflammatory responses and preservation of mucosal defense. Graphical Abstract
- 27 September 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (10) , 446
Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia and is associated with multiple systemic complications. Chronic hyperglycaemia and related metabolic disturbances can impair bone remodelling and compromise bone quality and microarchitecture, increasing skeletal vulnerability. The effects of different antidiabetic treatment combinations on diabetes-associated skeletal alterations remain insufficiently characterized. We investigated the effects of canagliflozin alone and in combination with metformin and fenugreek seed extract on glycaemic control and skeletal alterations in a high-fat diet (HFD)-streptozotocin (STZ)-induced diabetic rat model. Diabetes was induced in female Wistar rats using a HFD followed by STZ (35 mg/kg, intraperitoneally), and animals were treated orally for 12 weeks with canagliflozin (10 or 20 mg/kg), fenugreek seed extract (400 mg/kg), canagliflozin (10 mg/kg) plus metformin (200 mg/kg), or canagliflozin (10 mg/kg) plus metformin (200 mg/kg) and fenugreek seed extract (400 mg/kg). At the end of the treatment period, glycaemic and skeletal parameters were assessed, including serum insulin, HbA1c, serum TRAP activity, urinary calcium excretion, femoral trabecular microarchitecture and histological changes. Diabetic rats exhibited marked hyperglycaemia and deterioration of femoral trabecular microarchitecture, with reductions in bone volume fraction, trabecular thickness, trabecular number and connectivity density (Conn. D) and increases in trabecular separation and structural model index (SMI). Treatment with canagliflozin, fenugreek seed extract and combination regimens attenuated these diabetes-associated alterations. At week 12, the canagliflozin-metformin-fenugreek combination reduced fasting blood glucose by approximately 57.8% and HbA1c by approximately 47.4% compared with diabetic controls and was associated with improved trabecular microarchitectural parameters. Serum TRAP activity and urinary calcium excretion were also reduced by approximately 26.1% and 31.4%, respectively. Histological findings were consistent with the micro-computed tomography (micro-CT) observations. Overall, canagliflozin-based combination treatments were associated with improved metabolic control and attenuation of femoral trabecular deterioration in this experimental model, supporting further investigation of their skeletal effects and underlying mechanisms.
- 27 September 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (10) , 446
Assessment of monotherapy and combination therapy with canagliflozin, metformin, and fenugreek seed extract in experimental diabetic osteopathy
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia and is associated with multiple systemic complications. Chronic hyperglycaemia and related metabolic disturbances can impair bone remodelling and compromise bone quality and microarchitecture, increasing skeletal vulnerability. The effects of different antidiabetic treatment combinations on diabetes-associated skeletal alterations remain insufficiently characterized. We investigated the effects of canagliflozin alone and in combination with metformin and fenugreek seed extract on glycaemic control and skeletal alterations in a high-fat diet (HFD)-streptozotocin (STZ)-induced diabetic rat model. Diabetes was induced in female Wistar rats using a HFD followed by STZ (35 mg/kg, intraperitoneally), and animals were treated orally for 12 weeks with canagliflozin (10 or 20 mg/kg), fenugreek seed extract (400 mg/kg), canagliflozin (10 mg/kg) plus metformin (200 mg/kg), or canagliflozin (10 mg/kg) plus metformin (200 mg/kg) and fenugreek seed extract (400 mg/kg). At the end of the treatment period, glycaemic and skeletal parameters were assessed, including serum insulin, HbA1c, serum TRAP activity, urinary calcium excretion, femoral trabecular microarchitecture and histological changes. Diabetic rats exhibited marked hyperglycaemia and deterioration of femoral trabecular microarchitecture, with reductions in bone volume fraction, trabecular thickness, trabecular number and connectivity density (Conn. D) and increases in trabecular separation and structural model index (SMI). Treatment with canagliflozin, fenugreek seed extract and combination regimens attenuated these diabetes-associated alterations. At week 12, the canagliflozin-metformin-fenugreek combination reduced fasting blood glucose by approximately 57.8% and HbA1c by approximately 47.4% compared with diabetic controls and was associated with improved trabecular microarchitectural parameters. Serum TRAP activity and urinary calcium excretion were also reduced by approximately 26.1% and 31.4%, respectively. Histological findings were consistent with the micro-computed tomography (micro-CT) observations. Overall, canagliflozin-based combination treatments were associated with improved metabolic control and attenuation of femoral trabecular deterioration in this experimental model, supporting further investigation of their skeletal effects and underlying mechanisms.
- 1 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 9742-9746
One Model, Many Phenotypes: The Urgent Need to Standardise the High‐Fat Diet–Streptozotocin Model for Type 2 Diabetes
- 1 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 9742-9746
One Model, Many Phenotypes: The Urgent Need to Standardise the High‐Fat Diet–Streptozotocin Model for Type 2 Diabetes
- 10 August 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (9) , 5901-5917
From xanthine oxidase inhibition to inflammasome regulation: exploring the potential role of allopurinol in TXNIP–NLRP3 signaling and pyroptosis in diabetes
- 10 August 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (9) , 5901-5917
From xanthine oxidase inhibition to inflammasome regulation: exploring the potential role of allopurinol in TXNIP–NLRP3 signaling and pyroptosis in diabetes
- 14 July 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (9) , 3983-3994
Pharmacological Evaluation of Bexagliflozin Monotherapy and Combination Therapy with Rutin in Streptozotocin-Induced Diabetes-Associated Cardiac Injury in Rats
- 14 July 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (9) , 3983-3994
Pharmacological Evaluation of Bexagliflozin Monotherapy and Combination Therapy with Rutin in Streptozotocin-Induced Diabetes-Associated Cardiac Injury in Rats
- 14 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70780
Allopurinol Beyond Gout: Targeting Oxidative Stress and Metabolic Inflammation in Diabetes and Its Complications
- 14 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70780
Allopurinol Beyond Gout: Targeting Oxidative Stress and Metabolic Inflammation in Diabetes and Its Complications
- 23 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 986
From sugar to flames: the detrimental role of pyroptosis in diabetes-associated bone loss
Diabetes mellitus (DM) is increasingly recognized as a major risk factor for skeletal fragility, characterized by impaired bone quality and increased fracture susceptibility. Chronic hyperglycemia induces metabolic stress, oxidative injury, and low-grade inflammation, all of which disrupt normal bone remodeling. Accumulating evidence indicates that pyroptosis, a highly inflammatory form of programmed cell death, has emerged as a critical mechanistic link between diabetes and bone loss. Pyroptosis is driven by inflammasome activation, particularly the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, leading to caspase-1 activation, gasdermin-mediated membrane pore formation, and the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18 (IL-18). In the diabetic bone microenvironment, pyroptosis affects all major bone cell types. Osteoblast pyroptosis suppresses bone formation, osteoclast-associated pyroptotic signaling enhances bone resorption, and osteocyte pyroptosis disrupts mechanotransduction and microarchitectural integrity. Emerging data further reveal extensive crosstalk between pyroptosis, apoptosis, and necroptosis through PANoptotic signaling pathways, amplifying inflammatory bone damage. Experimental evidence from in vivo and in vitro models, together with emerging biomarker studies, consistently supports a central role for pyroptosis in diabetes-associated bone disease. Understanding the molecular regulation and temporal dynamics of pyroptosis in bone may provide novel therapeutic opportunities to preserve skeletal health in diabetic patients.
- 23 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 986
From sugar to flames: the detrimental role of pyroptosis in diabetes-associated bone loss
Diabetes mellitus (DM) is increasingly recognized as a major risk factor for skeletal fragility, characterized by impaired bone quality and increased fracture susceptibility. Chronic hyperglycemia induces metabolic stress, oxidative injury, and low-grade inflammation, all of which disrupt normal bone remodeling. Accumulating evidence indicates that pyroptosis, a highly inflammatory form of programmed cell death, has emerged as a critical mechanistic link between diabetes and bone loss. Pyroptosis is driven by inflammasome activation, particularly the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, leading to caspase-1 activation, gasdermin-mediated membrane pore formation, and the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18 (IL-18). In the diabetic bone microenvironment, pyroptosis affects all major bone cell types. Osteoblast pyroptosis suppresses bone formation, osteoclast-associated pyroptotic signaling enhances bone resorption, and osteocyte pyroptosis disrupts mechanotransduction and microarchitectural integrity. Emerging data further reveal extensive crosstalk between pyroptosis, apoptosis, and necroptosis through PANoptotic signaling pathways, amplifying inflammatory bone damage. Experimental evidence from in vivo and in vitro models, together with emerging biomarker studies, consistently supports a central role for pyroptosis in diabetes-associated bone disease. Understanding the molecular regulation and temporal dynamics of pyroptosis in bone may provide novel therapeutic opportunities to preserve skeletal health in diabetic patients.